Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure patients get Dual-Drug hope

NCT ID NCT06520891

Disease control Sponsor: Fayoum University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing whether taking a statin (atorvastatin) together with an SGLT2 inhibitor (dapagliflozin) helps people with ischemic heart failure. Researchers will measure cholesterol levels and other lab tests in 90 participants. The goal is to see if the combination works better than either drug alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atorvastatin (statin) and dapagliflozin (SGLT2i)
What this could lead to
If it works, this could show that taking both drugs together helps manage cholesterol and heart health better than either alone.
What could go wrong
This is a small, early-phase study with only 90 participants, so results may not apply to everyone. The trial focuses on lab tests, not long-term outcomes like survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

the health care provider asks about patient's symptoms which may experience: * Chest pain, especially after physical exertion * Dizziness or fainting * Heart palpitations, which may feel like your heart fluttering or skipping beats * Shortness of breath * Swelling in your feet or ankles * brain natriuretic peptide (BNP) with 70% sensitivity and 99% specificity and N-terminal proBNP (NT-proBNP) with 99% sensitivity and 85% specificity which are Other HF-specific laboratory tests (especially in patients with a high possibility of heart failure) included. (18) * chest X-ray, transthoracic echocardiography (TTE), computerized tomography (CT) scans and magnetic resonance imaging (MRI) also other diagnostic tests for HF. (19)

Ages

50 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * we include patients established ischemic heart failure seen by a primary care provider to diagnose ischemic heart disease, * They assessed the use of statin with SGLT2i. Exclusion Criteria: * We exclude patients with 1. liver dysfunction. 2. renal dysfunction. 3. fungal infection. 4. coagulation disorder. 5. Pts using drugs that interact with SGLT2i. 6. patients that will refuse to be enrolled in the Study or refuse to write informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 2 drugs are statin and SGLT2I are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

2 drugs are statin and SGLT2I

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asmaa mohamed abdelkader

    RECRUITING

    Al Fayyum, Faiyum Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.